PMID- 19088493
OWN - NLM
STAT- MEDLINE
DCOM- 20090416
LR  - 20221207
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 58
IP  - 3-4
DP  - 2008
TI  - Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met 
      polymorphism in anxiety disorders and anxiety-related personality traits.
PG  - 163-70
LID - 10.1159/000182892 [doi]
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is potentially involved in 
      the pathogenesis of anxiety. We carried out meta-analyses to evaluate the 
      relationship between the BDNF Val66Met (valine, methionine) polymorphism and 
      anxiety disorders (AD) or anxiety-related personality traits (ARPT). METHODS: 
      Medline, Embase and PsycINFO were searched up to December 2007. We investigated 3 
      outcomes related to BDNF Val66Met polymorphisms: (1) clinically diagnosed cases 
      of AD; (2) ARPT in subjects without psychiatric diagnoses, assessed either by the 
      Neuroticism scale of NEO-Personality Inventory forms (NEO-PI, NEO-PI-R, NEO-FFI), 
      or by (3) the Harm Avoidance (HA) scale of Tridimensional Personality 
      Questionnaire (TPQ) or its extended version Temperament and Character Inventory 
      (TCI). RESULTS: Seven case-control studies were selected for AD, including 1,092 
      cases and 8,394 controls, while 5 cross-sectional studies for Neuroticism (n = 
      1,633) and 4 for HA (n = 607). Both Met/Met and Val/Met individuals, as compared 
      to Val/Val, showed a statistically significant lower Neuroticism score [SMD = 
      -0.24 (95% CI: -0.44, -0.04), and -0.11 (95% CI: -0.22, -0.01), respectively]. No 
      significant association was found between BDNF Val66Met polymorphism and AD [OR = 
      1.13 (95% CI: 0.85-1.52) for Met/Met versus Val/Val] or HA [SMD = 0.11 (95% CI: 
      -0.19, 0.42) for Met/Met vs. Val/Val]. CONCLUSIONS: The low number of studies on 
      this topic and their limited sample size, along with the inner limits in the 
      definition of anxiety phenotypes, suggest caution in the interpretation of these 
      results. Larger additional studies possibly investigating the interaction with 
      other genes and environmental exposures are required to confirm these results.
CI  - 2008 S. Karger AG, Basel.
FAU - Frustaci, Alessandra
AU  - Frustaci A
AD  - Institute of Psychiatry and Psychology, Faculty of Medicine and Surgery 'A. 
      Gemelli', Catholic University of the Sacred Heart, Rome, Italy.
FAU - Pozzi, Gino
AU  - Pozzi G
FAU - Gianfagna, Francesco
AU  - Gianfagna F
FAU - Manzoli, Lamberto
AU  - Manzoli L
FAU - Boccia, Stefania
AU  - Boccia S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20081217
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Anxiety/*genetics
MH  - Anxiety Disorders/diagnosis/*genetics
MH  - Asian People/genetics
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Genetic Heterogeneity
MH  - Humans
MH  - Neuropsychological Tests
MH  - Odds Ratio
MH  - Personality/*genetics
MH  - *Polymorphism, Single Nucleotide
MH  - Surveys and Questionnaires
MH  - White People/genetics
EDAT- 2008/12/18 09:00
MHDA- 2009/04/17 09:00
CRDT- 2008/12/18 09:00
PHST- 2008/05/26 00:00 [received]
PHST- 2008/10/05 00:00 [accepted]
PHST- 2008/12/18 09:00 [entrez]
PHST- 2008/12/18 09:00 [pubmed]
PHST- 2009/04/17 09:00 [medline]
AID - 000182892 [pii]
AID - 10.1159/000182892 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2008;58(3-4):163-70. doi: 10.1159/000182892. Epub 2008 Dec 
      17.